Memphasys (ASX:MEM) confirmed the RoXsta Mega Cell High-Throughput Assay device was capable of simultaneously processing 96 samples in less than an hour during recent trials, according to a Thursday filing with the Australian bourse.
The diagnostic device has been developed for rapid and high-capacity testing of reactive oxygen species levels in biological fluids, the filing said.
The device has been utilized in various studies, including assessing oxidative stress in cattle and assessing antioxidant levels in professional footballers, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。